Whole-body MR in Staging Bone and Soft Tissue Metastases in Breast Cancer Patients(MetaMaRBo) (METAMARBO)
|ClinicalTrials.gov Identifier: NCT01291082|
Recruitment Status : Unknown
Verified January 2013 by Steven Pans, Universitaire Ziekenhuizen Leuven.
Recruitment status was: Recruiting
First Posted : February 7, 2011
Last Update Posted : January 29, 2013
|Condition or disease|
About 50 patients with a proven breast cancer and bone metastases will be included.
First step : staging
- nuclear bone scan
- Positron Emission Tomography (PET/CT)
- MR (whole body short tau inversion recovery (STIR)-sequence and T1-sequence and Diffusion weighted imaging (DWI),no contrast administration
- Validation of whole body diffusion weighted imaging in detection of bone metastases and visceral metastases, comparing to Bone scan en PET/CT results.
- To calculate cut-off values for DWI for bone and visceral metastases.
Second step : therapy follow-up/therapy assessment.
Two groups of patients (oncologist takes the decision about therapy)
- Patients treated by chemotherapy
- Patients treated by hormonal therapy
- on week 3, 12-16 and 52 in the chemotherapy or hormonal therapy-setting, a whole body MR (same protocol, no contrast) will be performed.
Whole body MR with DWI is useful and reliable to assess the treatment response.
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Whole-body Magnetische Resonantie Voor Het Opsporen Van Bot- en Weke Delenmetastasen Bij patiënten Met Een Borstcarcinoom (MetaMaRBo)|
|Study Start Date :||February 2011|
|Estimated Primary Completion Date :||April 2013|
|Estimated Study Completion Date :||August 2013|
Breast cancer patients
Breast cancer patients
- Validation of whole body diffusion weighted MRI in breastcancer patients [ Time Frame: 6 months ]whole body MRI will be correlated to the nucleair bone scan and PET-CT
- Whole body MRI with diffusion weighted imaging is a reliable imaging tool for therapy assessment [ Time Frame: 12 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01291082
|Contact: Steven Pansemail@example.com|
|University Hospitals Leuven||Recruiting|
|Leuven, Belgium, 3000|
|Contact: Steven Pans, MD 003216340505 firstname.lastname@example.org|
|Principal Investigator: Steven Pans, MD|
|Principal Investigator:||Steven Pans, MD||UZ Leuven Dept Radiology|